SBIR-STTR Award

Fecal Dna Testing For Colorectal Cancer Screening
Award last edited on: 10/30/14

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$225,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Baochuan Guo

Company Information

GLC Biotechnology Inc (AKA: GLC)

7362 Stcokwood Drive
Solon, OH 44139
   (330) 405-0858
   glc@glcbiotech.com
   www.glcbiotech.com
Location: Single
Congr. District: 14
County: 

Phase I

Contract Number: 1R43CA183170-01A1
Start Date: 5/1/14    Completed: 1/31/15
Phase I year
2014
Phase I Amount
$225,000
This is the Phase I application of a SBIR project that will be devoted to develop a new fecal DNA test for CRC screening, which will utilize a new tri-marker panel discovered in our preliminary study. CRC is the second deadliest cancer in USA. The good news is that early detection along with resection is associated with a five-year survival rate of nearly 100%. Fecal DNA testing is emerging as one of the most promising methods to replace fecal occult blood tests for CRC screening. Recently, we discovered a new panel of stool DNA markers that could detect 86% of CRC with a specificity of 82%. Because this new panel contains no methylated DNA markers, a great benefit of using it for CRC screening is that the quantity of the stool used to extract DNA could be reduced by at least 10 fold, greatly reducing the complexity and cost of fecal DNA testing. To the best of our knowledge, this may be the simplest panel of markers that can achieve such high detection sensitivity with good specificity. The specific aim of this Phase I project is to validate this new marker panel for CRC screening. The validation will be carried out using the training-test set procedure. The milestone set for Phase I is to demonstrate that the new marker panel can detect ~85% of CRC with a specificity of ~80%.

Thesaurus Terms:
Adenoma;Advisory Committees;American;Base;Biological Assay;Blood Tests;Clinical;Colorectal Cancer Screening;Compliance Behavior;Cost;Cost Effective;Design;Detection;Development;Dna;Dna Analysis;Dna Markers;Early Diagnosis;Excision;Fecal Occult Blood;Feces;Fusobacterium Nucleatum;Healthcare;Improved;Innovation;Mails;Malignant Neoplasms;Methods;Molecular;News;Novel Marker;Office Visits;Patients;Performance;Phase;Physicians;Preparation;Procedures;Public Health Relevance;Recruitment Activity;Research Clinical Testing;Sample Size;Sampling;Screening;Screening For Cancer;Sensitivity And Specificity;Small Business Innovation Research Grant;Societies;Specificity;Specimen;Success;Survival Rate;Testing;Training;Validation;Validation Studies;Weight;

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----